Episode 6 of the Therapeutic Science and Strategy Podcast Series recorded by Lumanity

In this sixth episode, Joel sits down with Pierre d’Epenoux, CEO, ImCheck Therapeutics and Paul Frohna, CMO, ImCheck Therapeutics, to explore:

  • Company origins, focus, and fundraising performance to date
  • Role of butyrophilins (BTNs) as an novel therapeutic target to boost antitumor immunity
  • Performance of ICT01, Imcheck’s clinical-stage lead program targeting BTN3A in gamma-delta T-cells
  • Positioning and commercial strategy in the post-PD1 solid-tumor landscape

Podcast Series: Therapeutic Science and Strategy

In this podcast series, Joel Sandler, Principal, BioConsulting, Cancer Cell Therapy Lead, sits down to talk about relevant and important content.